Today is #EmployeeAppreciationDay, and at Menarini Stemline, we’re taking a moment to celebrate the team behind our mission.
From the lab to the field, and every department in between, our team’s passion for transforming oncology care is what drives us forward.
Honored to participate as honorary president of BGICC 2026, on the podium with world health care leaders in Cairo. Discussion focused on collectively resolving massive health care disparities. Kudos Hesham Elghazaly. @OncoAlert @curijoey @lynn_schuchter
Today is 1/23. For the #BPDCN community, this date is a powerful reminder of #CD123 — a crucial diagnostic marker as well as a target for precision BPDCN therapies.
On this day, Menarini Stemline renews its dedication to advancing innovation and research to improve outcomes for individuals living with Blastic Plasmacytoid Dendritic Cell Neoplasm, a highly aggressive orphan hematologic malignancy. Learn more at https://t.co/bgQJQypTTK
#MenariniStemline
Happy New Year from Menarini Stemline! As we proudly step into 2026, our entire team is energized and eager to accelerate innovation in cancer treatment. We are looking forward to another great year!
#MenariniStemline
On this day of giving thanks, we are extremely grateful for the support and collaboration of healthcare providers, our employees and colleagues who help drive our work, and the patients and families who inspire us every day. We wish you all a joyful holiday!
#Thanksgiving #MenariniStemline
ORSERDU has efficacy in the EMERALD trial
and has real-world evidence in clinical
practice. Visit the ESR1 mBC RWE website
linked in the description to see the latest data.
Please see full Prescribing Information at link in bio.
Today, on #NationalSTEMDay, we recognize the power of science, technology, engineering, and mathematics. At Menarini Stemline we are proud to honor our colleagues in these fields who help drive progress in healthcare, so that together, we can keep improving patient care.
#MenariniStemline
Real-world elacestrant data from #SethWander and his colleagues now out. Rare to see RWE outperform the registrational trial: in this cohort, median TTNT approaches 9 months; exceeding EMERALD.
Strong signal elacestrant delivers in routine practice for ESR1-mutant HR+/HER2– mBC.
https://t.co/Tax4DkrX4L
Real-world outcomes with elacestrant, out on @CCR_AACR. Among 742 patients treated with elacestrant and with an ESR1 mutation detected within 6 months, TTNT was 6.4 months, TTD 4.6 months. Similar outcomes observed among pts with both ESR1 and PIK3CA mut. https://t.co/JXw6WiSbrV
Larry Norton awarded the ABC8 award for his lifelong and practice changing work and dedication to current and future research in breast cancer. A mentor to so many including me - and a passionate clinician @BCRFcure @ABCGlobalAll @OncoAlert
We are excited to announce that the Menarini Stemline team will be attending the Advanced Breast Cancer International Consensus Conference (ABC8) in Lisbon! We look forward to connecting with the breast cancer community and sharing our latest insights. Come visit us at booth #2 to learn more about our work and connect with our team.
#ABCLisbon #BreastCancer #MenariniStemline
The Menarini Stemline team is on its way to National Harbor, Maryland for the JADPRO Live 2025 conference! If you’re onsite, we'd love to connect at our booth and at the puppy station in the exhibit hall, which we are proud to sponsor this year.
#JADPRO#JADPROLive #MenariniStemline